Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - IONIS PHARMACEUTICALS INC | ex99_1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 5, 2015
ISIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
000-19125
|
33-0336973
|
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On January 5, 2015, Isis Pharmaceuticals, Inc. (the “Company”) announced that Sarah Boyce, age 43, has joined the Company as chief business officer. In this newly created position, Ms. Boyce will provide strategic leadership from a commercial background and lead Isis’ corporate development activities, including corporate communications, business development, patient advocacy, competitive intelligence and alliance management. Ms. Boyce will report to B. Lynne Parshall, chief operating officer of the Company and will also serve as a member of Isis’ executive leadership team.
A copy of the press release announcing Ms. Boyce’s position is included with this report as exhibit 99.1 and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| 99.1 | Press Release dated January 5, 2015. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Isis Pharmaceuticals, Inc.
|
||
|
Dated: January 5, 2015
|
By:
|
/s/ B. Lynne Parshall
|
|
B. Lynne Parshall
|
||
|
Chief Operating Officer
|
||
INDEX TO EXHIBITS
| 99.1 | Press Release dated January 5, 2015. |